NCT06804460

Brief Summary

This study aims to evaluate the effect of a vegan Mediterranean diet compared to a traditional Mediterranean diet on inflammatory biomarkers, functional capacity, and quality of life in patients with fibromyalgia.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
28

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started Mar 2025

Shorter than P25 for phase_1

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 27, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 3, 2025

Completed
26 days until next milestone

Study Start

First participant enrolled

March 1, 2025

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 14, 2025

Completed
7 days until next milestone

Study Completion

Last participant's last visit for all outcomes

April 21, 2025

Completed
Last Updated

February 3, 2025

Status Verified

January 1, 2025

Enrollment Period

1 month

First QC Date

January 27, 2025

Last Update Submit

January 31, 2025

Conditions

Keywords

Fibromyalgia

Outcome Measures

Primary Outcomes (5)

  • Neutrophil to lymphocyte ratio

    Lymphocyte and neutrophil concentrations will be measured with the HemoCue® WBC DIFF system (HemoCue AB, Ängelholm, Sweden).The Neutrophil-to-Lymphocyte Ratio (NLR) is a simple inflammatory biomarker calculated by dividing neutrophil count by lymphocyte count. It reflects the balance between inflammation (neutrophils) and immune regulation (lymphocytes). An elevated NLR is associated with chronic inflammation, physiological stress, or immune dysfunction, while lower levels indicate a more balanced immune state. Its ease of measurement and broad applicability make it valuable for monitoring inflammatory, cardiovascular, and oncological conditions.

    From enrollment to the end of treatment at 6 weeks

  • Lipid profile

    The concentrations of total cholesterol and cholesterol-LDL will be measured with a POC multi-parameter lux meter (Biochemical Systems International, Italy).

    From enrollment to the end of treatment at 6 weeks

  • Cardiorespiratory fitness

    The 30s Chair-to-Stand (CS) test assesses lower trunk strength by counting how many times a person can stand up and sit down within 30 seconds. It is commonly used to evaluate functional mobility and endurance in older adults or individuals with certain health conditions.

    From enrollment to the end of treatment at 6 weeks

  • Quality life

    The Fibromyalgia Impact Questionnaire (FIQ) examines the impact of fibromyalgia on daily life, covering areas such as functional capacity, pain, fatigue, sleep, and psychological well-being. Its revised version (FIQ-revised) focuses more on functional capacity, symptoms, and the overall impact of fibromyalgia on the individual's daily life.

    From enrollment to the end of treatment at 6 weeks

  • Metabolic health

    Visceral fat is the fat stored within the abdominal cavity around internal organs. It is commonly measured to assess the risk of metabolic diseases, such as type 2 diabetes and cardiovascular conditions.

    From enrollment to the end of treatment at 6 weeks

Secondary Outcomes (5)

  • Metabolic health

    From enrollment to the end of treatment at 6 weeks

  • Metabolic health

    From enrollment to the end of treatment at 6 weeks

  • Strength performance

    From enrollment to the end of treatment at 6 weeks

  • Quality Life

    From enrollment to the end of treatment at 6 weeks

  • Quality life

    From enrollment to the end of treatment at 6 weeks

Study Arms (2)

Vegan Mediterranean diet

EXPERIMENTAL

The vegan mediterranean diet is mainly composed of whole plant-based foods, similar to a Mediterranean diet, but the animal sources of protein and fat are substituted with plant foods rich in protein and fat. During the vegan diet, participants are supplemented with 1000 µg of cyanocobalamin (vitamin B12) twice a week (Harrison Sports Nutrition, Granada, Spain) to compensate for the deficiency in vitamin B12 intake induced by the vegan diet.

Behavioral: Dietary intervention

Mediterranean diet

ACTIVE COMPARATOR

The traditional Mediterranean diet contains an abundant intake of whole plant-based foods, with moderate to low consumption of fish, poultry, low-fat dairy products, and eggs, very low consumption of red and processed meats, and no sweets. Olive oil is the main added fat, and animal protein accounts for 60% of total protein intake.

Behavioral: Dietary intervention

Interventions

The vegan mediterranean diet is mainly composed of whole plant-based foods, similar a una dieta mediterránea, but the animal sources of protein and fat are substituted with plant foods rich in protein and fat. During the vegan diet, participants are supplemented with 1000 µg of cyanocobalamin (vitamin B12) twice a week (Harrison Sports Nutrition, Granada, Spain) to compensate for the deficiency in vitamin B12 intake induced by the vegan diet.

Mediterranean dietVegan Mediterranean diet

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Adults aged between 18 and 50 years.
  • Participants with a Fibromyalgia diagnosis according to the American College of Rheumatology (ACR) criteria.
  • Functional independence.
  • Non-smokers.
  • Low alcohol consumption (\<1 serving/day).
  • Pharmacological treatment stabilized for at least 4 weeks prior to the start of the study.

You may not qualify if:

  • Pregnant, lactating, or menopausal women.
  • Physical condition that prevents the performance of functional capacity tests.
  • Change in pharmacological therapy during the intervention period.
  • Concomitant inflammatory conditions.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Fibromyalgia

Interventions

Diet Therapy

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesRheumatic DiseasesNeuromuscular DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

Nutrition TherapyTherapeutics

Central Study Contacts

Miguel Dr. López Moreno, PhD

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

January 27, 2025

First Posted

February 3, 2025

Study Start

March 1, 2025

Primary Completion

April 14, 2025

Study Completion

April 21, 2025

Last Updated

February 3, 2025

Record last verified: 2025-01

Data Sharing

IPD Sharing
Will not share

In our study, the sharing of individual participant data (IPD) is not required as part of the trial registration process on ClinicalTrials.gov. The study does not involve sharing identifiable participant information or IPD for secondary analyses or public access